Literature DB >> 6589425

Cancer mortality in relatives of retinoblastoma patients.

L C Strong, J Herson, C Haas, K Elder, R Chakraborty, K M Weiss, P Majumder.   

Abstract

The risk of other cancers in relatives of retinoblastoma (RTB) patients was determined by a survey of the mortality experience of siblings, parents, parental siblings, and grandparents of all U.S. or Canadian RTB patients referred to The University of Texas M.D. Anderson Hospital and Tumor Institute between 1944 and 1980. Expected mortality was ascertained by the application of age-, sex-, race-, and calendar year-specific U.S. mortality rates to the observed person-years. Among 607 relatives of 33 unilateral-sporadic RTB probands, no excess in cancer deaths was observed (observed/expected = 18/22). Among 733 relatives of 47 bilateral-familial RTB probands, a slight excess in cancer deaths was observed (41/31). A significant excess in cancer deaths was occurred in relatives under age 55 years (18/9) and in fathers (7/1) of the bilateral RTB probands. To determine whether the cancer excess was related to some unique allele associated with second tumors in RTB survivors, the cancer mortality of 203 relatives of the 14 RTB patients with second tumors was examined, and no excess was observed (11/11). To determine whether the excess might be attributable to an unexpressed RTB gene or precursor, the mortality experience was examined in 6 kindreds in which parents, unaffected by RTB, had more than 1 child with RTB. Among these 72 relatives a significant excess in cancer deaths was observed (8/2). The findings demonstrate a modest overall cancer excess in relatives of hereditary RTB patients and suggest it may be attributable to an unexpressed RTB gene or precursor in a small number of kindreds. Mechanisms for an apparent "precursor" might involve a delayed mutation, genetic mosaicism, or a submicroscopic balanced chromosomal translocation.

Entities:  

Mesh:

Year:  1984        PMID: 6589425     DOI: 10.1093/jnci/73.2.303

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  8 in total

1.  Effective testing of gene-disease associations.

Authors:  M Swift; L L Kupper; C L Chase
Journal:  Am J Hum Genet       Date:  1990-08       Impact factor: 11.025

2.  Association between CLPTM1L polymorphisms (rs402710 and rs401681) and lung cancer susceptibility: evidence from 27 case-control studies.

Authors:  De-ping Zhao; Chen-lu Yang; Xiao Zhou; Jia-an Ding; Ge-ning Jiang
Journal:  Mol Genet Genomics       Date:  2014-06-07       Impact factor: 3.291

3.  Risk of nonocular cancer in first-degree relatives of retinoblastoma patients.

Authors:  J H Olsen; J Winther; P N Brown
Journal:  Hum Genet       Date:  1990-08       Impact factor: 4.132

4.  Cumulative effect of multiple loci on genetic susceptibility to familial lung cancer.

Authors:  Pengyuan Liu; Haris G Vikis; Yan Lu; Yian Wang; Ann G Schwartz; Susan M Pinney; Ping Yang; Mariza de Andrade; Adi Gazdar; Colette Gaba; Diptasri Mandal; Juwon Lee; Elena Kupert; Daniela Seminara; John Minna; Joan E Bailey-Wilson; Christopher I Amos; Marshall W Anderson; Ming You
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-02       Impact factor: 4.254

5.  Malignant melanoma of the choroid in a mother and retinoblastoma in her son.

Authors:  S Hayasaka; K Mizuno
Journal:  Br J Ophthalmol       Date:  1986-02       Impact factor: 4.638

6.  Retinoblastoma function is essential for establishing lung epithelial quiescence after injury.

Authors:  Nicole A Mason-Richie; Meenakshi J Mistry; Caitlin A Gettler; Asmaa Elayyadi; Kathryn A Wikenheiser-Brokamp
Journal:  Cancer Res       Date:  2008-06-01       Impact factor: 12.701

7.  Non-ocular cancer in relatives of retinoblastoma patients.

Authors:  B M Sanders; M Jay; G J Draper; E M Roberts
Journal:  Br J Cancer       Date:  1989-09       Impact factor: 7.640

8.  Second primary neoplasms in patients with retinoblastoma.

Authors:  G J Draper; B M Sanders; J E Kingston
Journal:  Br J Cancer       Date:  1986-05       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.